"Rheumatology providers at this clinic: Philip J. Mease, MD; Peter Mohai, MD; Jan L. Hillson, MD; Daniel E. Furst, MD; Aneet Kaur, MD; Christy A. Vath, PA-C; Melissa M. Fessel, ARNP. All providers are accepting new patients. Providers at Seattle Rheumatology Associates diagnose and treat diseases affecting the body's connective tissue - musculoskeletal and inflammatory illnesses like rheumatism, arthritis (inflammatory, rheumatoid, etc.), osteoporosis, autoimmune diseases and other disorders of the joint, muscles and ligaments. Using proven clinical methodology, state-of-the-art treatments, techniques and the latest research, we help patients live the best life possible. We have an in-clinic infusion suite for our patients' convenience."

During the past decade, Seattle Rheumatology Associates conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 21 clinical trials were completed, i.e. on average, 175% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 13 clinical trials were completed. i.e. 325% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Seattle Rheumatology Associates" #1 sponsor was "Pfizer" with 7 trials, followed by "Amgen" with 3 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Genentech, Inc." with 3 trials sponsored and "CSL Behring" with 3 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Seattle Rheumatology Associates" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Affibody" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Columbia University" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Seattle Rheumatology Associates" are "Psoriatic Arthritis" (7 trials), "Rheumatoid Arthritis" (6 trials), "Ankylosing Spondylitis" (3 trials), "Arthritis, Psoriatic" (3 trials) and "Arthritis, Rheumatoid" (3 trials). Many other conditions were trialed in "Seattle Rheumatology Associates" in a lesser frequency.

Most popular intervention types in "Seattle Rheumatology Associates" are "Drug" (27 trials), "Other" (4 trials), "Biological" (3 trials), "Combination Product" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Methotrexate" (4 trials), "Adalimumab" (3 trials), "Etanercept" (3 trials) and "Abatacept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Seattle Rheumatology Associates" are 29 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Seattle Rheumatology Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Seattle Rheumatology Associates, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Seattle Rheumatology Associates, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".